

## OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200  
Hartford, CT 06106 ◊ (860) 240-0200  
<http://www.cga.ct.gov/ofa>

---

sHB-7267

AN ACT CONCERNING PUBLIC OPTIONS FOR HEALTH CARE IN  
CONNECTICUT.

### AMENDMENT

LCO No.: 10094

File Copy No.: 353

House Calendar No.: 231

---

### ***OFA Fiscal Note***

### ***See Fiscal Note Details***

The amendment strikes the underlying bill and its associated fiscal impact. It results in the following fiscal impacts:

**Sections 1 to 7, 9, 11, and 20** result in costs to the Office of Health Strategy (OHS) of less than approximately \$1 million in FY 20 and less than approximately \$1.5 million in FY 21 for staffing and contracting costs that will be incurred to fulfil the reporting, benchmarking, and reinsurance program requirements included in the amendment. Staffing costs reflect, at most, three Principal Health Care Analysts with salaries of approximately \$100,000 and an Administrative Assistant with a salary of approximately \$60,000. Associated fringe benefit costs are approximately \$500,000 annually.

**Section 10** establishes an excise tax on opioids which results in (1) a General Fund revenue gain of \$9.1 million in FY 20 and \$18.3 million annually thereafter, and (2) a one-time cost to the Department of Revenue Services of \$70,000 in FY 20 only associated with updates to the online Taxpayer Service Center and the internal Integrated Tax Administration System.

**Section 11** will result in an annual revenue gain of approximately at least \$19.2 to \$21.2 million from the fee imposed by the Insurance

Primary Analyst: RDP  
Contributing Analyst(s):

5/30/19  
(FN)

Department on insurance carriers to fund to reinsurance program. The revenue assumes at least \$25.6 to \$28.4 million in federal pass-through funding is secured through approval of a 1332 waiver. The reinsurance program will be operated by the existing Health Reinsurance Association which is a nonprofit association made of up Connecticut insurance carriers. Administering the fee and adopting regulations is not anticipated to result in a fiscal impact to the Insurance Department as it is within the agency's expertise.

**Sections 12 to 19**, which require the Department of Consumer Protection (DCP) and the Department of Public Health (DPH) to establish a Canadian Prescription Drug Importation Program, result in a cost to both agencies and the Office of the State Comptroller for fringe benefits. There is a potential revenue gain from laboratories that apply for certification to participate in the Program. Pursuant to CGS Sec. 19a-29a, the fee per laboratory certification application is \$1,250.

DCP and DPH will have to hire one 6-month durational Project Manager, at a cost of \$105,893 for salary and fringe benefits, to submit a program approval request to the federal Secretary of Health and Human Services (HHS). HHS approval is needed before the Canadian Prescription Drug Importation Program can be established. If the Program is approved by HHS, DCP will need one Drug Control Agent, resulting in a cost of \$119,171 for salary and fringe benefits, to regulate and enforce it. DPH will need a Laboratory Consultant at a cost of \$75,028 for salary and \$30,904 for fringe benefits. Among other tasks, the Laboratory Consultant will assess environmental laboratory applications for certification and evaluate testing protocols for each of the medications being reviewed for incorporation into the Program. Evaluation is needed to ensure quantitative and qualitative consistency with the United States Pharmacopeia.

**Section 21** does not result in a fiscal impact to the state or municipalities as it pertains to individual insurance policies.

---

*The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely for the purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.*